Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A gene famous for driving cancer may also be accelerating aging. Scientists found that CCND1—which encodes the protein cyclin D1—drives chronic inflammation in senescent ("zombie") cells, contributing to age-related disease. Blocking it with the breast cancer drug palbociclib reduced inflammation and improved physical function in older mice, hinting at a potential new use for the drug in healthy aging.
A gene long known for its role in cancer may have a hidden second job: stoking the chronic inflammation that drives age-related disease. Researchers at Sanford Burnham Prebys and collaborators published findings in Nature Aging showing that CCND1—the gene encoding cyclin D1—is highly active in senescent cells, the so-called "zombie" cells that stop dividing to prevent cancer but linger in the body and leak inflammatory signals.
The team found that cyclin D1, together with its partner molecule CDK6, amplifies the inflammatory secretions of senescent cells (known as SASP) by promoting DNA damage. This was confirmed in mouse models, where aged livers showed cyclin D1 accumulation and elevated inflammatory gene expression. Crucially, mice engineered to lack cyclin D1—or treated with the FDA-approved breast cancer drug palbociclib—showed less liver DNA damage, lower inflammation, and better physical function.
Key Takeaways:
Why it matters: This research opens a compelling new avenue for repurposing existing cancer drugs to combat age-related inflammation and frailty—potentially offering a faster path to clinical translation than developing entirely new therapies.
